Cortical Changes in Epilepsy Patients With Focal Cortical Dysplasia: New Insights With T2 Mapping

Rida Ahmad,1,2,3,4 Michelle Maiworm,1,2,3,4 Ulrike Nöth, PhD,3,4 Alexander Seiler, MD,1,3 Elke Hattingen, MD,2,4 Helmuth Steinmetz, MD,1,4 Felix Rosenow, MD,1,4,5 Ralf Deichmann, PhD,3,4 Marlies Wagner, MD,2,4 and René-Maxime Gracien, MD1,3,4*

Background: In epilepsy patients with focal cortical dysplasia (FCD) as the epileptogenic focus, global cortical signal changes are generally not visible on conventional MRI. However, epileptic seizures or antiepileptic medication might affect normal-appearing cerebral cortex and lead to subtle damage.

Purpose: To investigate cortical properties outside FCD regions with T2-relaxometry.

Study Type: Prospective study.

Subjects: Sixteen patients with epilepsy and FCD and 16 age-/sex-matched healthy controls.

Field Strength/Sequence: 3T, fast spin-echo T2-mapping, fluid-attenuated inversion recovery (FLAIR), and synthetic T1-weighted magnetization-prepared rapid acquisition of gradient-echoes (MP-RAGE) datasets derived from T1-maps.

Assessment: Reconstruction of the white matter and cortical surfaces based on MP-RAGE structural images was performed to extract cortical T2 values, excluding lesion areas. Three independent raters confirmed that morphological cortical/juxtacortical changes in the conventional FLAIR datasets outside the FCD areas were definitely absent for all patients. Averaged global cortical T2 values were compared between groups. Furthermore, group comparisons of regional cortical T2 values were performed using a surface-based approach. Tests for correlations with clinical parameters were carried out.

Statistical Tests: General linear model analysis, permutation simulations, paired and unpaired t-tests, and Pearson correlations.

Results: Cortical T2 values were increased outside FCD regions in patients (83.4 ± 2.1 msec, control group 81.4 ± 2.1 msec, P = 0.01). T2 increases were widespread, affecting mainly frontal, but also parietal and temporal regions of both hemispheres. Significant correlations were not observed (P ≥ 0.55) between cortical T2 values in the patient group and the number of seizures in the last 3 months or the number of anticonvulsive drugs in the medical history.

Data Conclusion: Widespread increases in cortical T2 in FCD-associated epilepsy patients were found, suggesting that structural epilepsy in patients with FCD is not only a symptom of a focal cerebral lesion, but also leads to global cortical damage not visible on conventional MRI.

Evidence Level: 21
Technical efficacy Stage: 3
patients, suggesting that patients with FCD exhibit focal rather than global pathological changes.

However, volumetric magnetic resonance imaging (MRI) studies have indicated global structural abnormalities in epilepsy patients, demonstrating multifocal gray matter (GM) volume changes in patients with malformations of cortical development other than FCD and generalized volume loss in 41% of the patients with chronic epilepsy. Apart from the adverse effects of antiepileptic medication such as neurotoxic side effects, long-standing epileptic activity might affect the cortex, leading to microstructural damage. Such cortical changes might, in addition to incomplete resections, at least in part, explain why approximately half of patients are not seizure-free after FCD resection.

Previous volumetric studies in epilepsy employed conventional MRI techniques that allow for quantification of volume changes such as atrophy but do not assess the underlying microstructural abnormalities. In contrast, quantitative MRI (qMRI) techniques measure actual tissue parameters, such as the T2 relaxation time, reducing effects of the scanner hard- and software. T2 relaxometry allows for the assessment of diffuse or inconspicuous changes in tissue architecture, such as abnormalities in relative myelin, iron, or free water content. Bernasconi et al observed hippocampal T2 changes in temporal lobe epilepsy (TLE), even in patients showing no signs of atrophy. In addition, qMRI data can help to distinguish between patients with TLE and healthy subjects. Furthermore, hippocampal profiling using volumetry and T2 values aids to spatially localize hippocampal MRI abnormalities. Reeves et al described T1 and T2 differences between the FCD region of interest in white matter (WM) and normal-appearing WM and magnetization transfer ratio changes in cortical GM inside FCDs, indicating microstructural abnormalities; however, the normal-appearing cortex was not investigated for abnormalities.

The main purpose of our study was to investigate T2 values in normal-appearing cortical tissue in patients with FCD, hypothesizing that pathologic tissue changes exceed FCD areas in epilepsy patients.

Materials and Methods

Participants

This study was approved by the local Ethics Committee, and participants gave written informed consent before participation. The study was conducted according to the principles expressed in the Declaration of Helsinki.

Inclusion criteria of the study were: patients with epilepsy and neuroradiologically diagnosed FCD and age- and sex-matched healthy subjects. Exclusion criteria were: other neurological or psychiatric disorders, MRI contraindications, uncontrolled arterial hypertension, or diabetes mellitus.

Sixteen patients (13 male, age: mean ± SD: 27.6 ± 10.3 years) and 16 matched healthy subjects (13 male, age: mean ± SD: 27.3 ± 9.4 years) were investigated. Recruitment was performed in 2018 and 2019 at Goethe University Hospital. The presence or absence of the typical transmantle sign was evaluated based on conventional fluid-attenuated inversion recovery (FLAIR) data (acquisition parameters as detailed below in the section “MRI acquisition and T2 mapping”) for each subject by an experienced neurologist (10 years of experience) and by a senior neuroradiologist specialized in epilepsy imaging (15 years of experience), making decisions by consensus. The number of seizures during a period of 3 months before data acquisition and the number of anticonvulsive drugs in the medical history were obtained anamnestically. In case patients underwent resection, pathology reports were reviewed. In addition, the report of the last electroencephalography (EEG) recording before MRI data acquisition was taken into account for each patient in order to correlate EEG findings with FCD locations. The study presented here is part of a larger prospective scientific project addressing different research questions. Accordingly, the group of patients and healthy control subjects and the acquired data overlap in part with those of previous studies with different aims, presenting novel methods for FCD detection or creating improved synthetic T1-weighted datasets.

MRI Acquisition and T2 Mapping

Data acquisition was performed using a 3T MR scanner (Magnetom Trio, Siemens Healthineers, Erlangen, Germany). The system utilizes a body coil for radiofrequency (RF) transmission and an 8-channel phased-array head coil for signal reception.

Custom-built programs were used for data analysis, employing functions included in MatLab (MathWorks, Natick, MA), FreeSurfer (Athinoula A. Martinos Center for Biomedical Imaging, Boston, MA), and the FMRIB Software Library (FSL, Oxford, UK).

For voxelwise measurement of the T2 relaxation time, four fast spin echo datasets with different echo times (TEs) were acquired using the following acquisition parameters: matrix size = 256 × 176, number of axial slices = 69, slice thickness = 2 mm, no interslice gap, slice coverage of 138 mm (whole brain), spatial resolution = 1 × 1 × 2 mm3, resulting field of view = 256 × 176 mm², TE = 13, 67, 93, and 106 msec, repetition time (TR) = 10 seconds, bandwidth = 176 Hz/pixel, refocusing angle = 160°, turbo factor = 13, parallel imaging with a reduction factor of 2, and acquisition time for each dataset = 1 minute 32 seconds. Each of the datasets was acquired twice for averaging, resulting in a total acquisition time of 12 minutes 16 seconds.

To correct for subject motion, all datasets were first registered to a common target. For each TE, the two respective datasets were then averaged. Exponential fitting of the dependence between TE and the signal intensities in the averaged datasets yielded apparent T2 values (T2app). It has been shown that T2app can deviate considerably from the true T2 value if the actual refocusing angle deviates from the ideal value of 180°, yielding stimulated or secondary echoes. This can be due to B1 inhomogeneities, deviations of the slice profile from a perfectly rectangular shape or deliberate choice of a reduced refocusing angle to reduce the RF power, as in this study. Thus, a B1-dependent correction was performed, converting T2app into actual T2 values as described previously. To allow for whole-brain coverage at a feasible imaging time, only four TE values were chosen. However, a previous study
showed that a similar protocol yielded accurate $T_2$ mapping with a scan–rescan deviation of about only 1.5%.\textsuperscript{26} For FCD definition, conventional FLAIR datasets were obtained with the following acquisition parameters: matrix size = $256 \times 220 \times 160$, isotropic resolution = 1 mm, field of view = $256 \times 220 \times 160$ mm$^3$, TE = 353 msec, TR = 5000 msec, inversion time (TI) = 1800 msec, bandwidth = 930 Hz/pixel, duration = 7 minutes 12 seconds.

For tissue segmentation, synthetic $T_1$-weighted magnetization-prepared rapid acquisition of gradient echoes (MP-RAGE) datasets were derived from quantitative $T_2$ maps using the same MR protocols (total duration = 16 minutes 43 seconds) and postprocessing algorithms as described previously\textsuperscript{29} and assuming the following virtual acquisition parameters: matrix size = $256 \times 224 \times 160$, isotropic resolution = 1 mm$^3$, field of view = $256 \times 224 \times 160$ mm$^3$, TR = 1900 msec, TI = 900 msec, flip angle ($\alpha$) = 9°, echo spacing = 8.1 msec.

### Statistical Analysis

Mean cortical $T_2$ values were determined across all non-zero vertices for each subject, as discussed in a previous study,\textsuperscript{30} and compared between groups with an unpaired $t$-test. The Pearson correlation coefficients between these values and clinical parameters (number of seizures in the previous 3 months and number of anticonvulsive drugs in the medical history, including current treatment) were calculated. Additionally, $T_2$ values were averaged separately for each hemisphere and compared via paired $t$-tests between the hemispheres where the FCD was located and the contralateral side across the patient cohort. Compensation for multiple comparisons was performed via the Benjamini–Hochberg / False Discovery Rate (FDR) method for the respective statistical tests (comparing average cortical $T_2$ values between all patients and healthy subjects, estimating the correlation of $T_2$ and clinical parameters, and comparing $T_2$ between the hemispheres). A secondary comparison of mean cortical $T_2$ values was performed between the subgroup with a low seizure rate ($\leq$12 seizures in the 3 months before data acquisition) and the control group to eliminate the effects of patients with aggressive disease.

Surface-based group analysis was performed for cortical $T_2$ values and for the cortical thickness. The $T_2$ surface data and cortical thickness maps were normalized and smoothed with a Gaussian kernel (full-width at half-maximum of 1 cm). A General Linear Model (GLM) analysis was performed for group comparisons. For a given region, only the data from patients without a local FCD in this region were included in the GLM calculation. Permutation simulations were performed for vertices with significant $P$ values ($<0.05$) to detect clusters indicating group differences and to correct for multiple comparisons (5000 simulations, clusterwise threshold = 0.05).

An FDR of 0.05 was chosen for the Benjamini–Hochberg procedure. Corrected $P$ values below 0.05 were considered significant for the surface-based analysis.

### Results

The number of seizures of the 16 FCD patients during a period of 3 months before the investigation was 130 $\pm$ 293 (mean $\pm$ standard deviation, SD). However, 11 of the patients had equal to or less than 12 seizures during this time. The number of anticonvulsive drugs in medical history including current treatment was 4.1 $\pm$ 2.2 (range 1–7). Ten of the 16 patients had an FCD with a positive transmantle sign. Figure S1 in the Supplemental Material shows the FCDs in FLAIR and MP-RAGE datasets for three representative patients. The three independent raters found that morphological cortical and juxtacortical changes outside the FCD areas were definitely absent for all patients. For three patients, the FCD type was histopathologically confirmed after data acquisition and resection (1x type IIa and 2x type IIb). EEG recordings revealed abnormalities at the FCD locations in 12 patients (findings indicating structural abnormalities in seven patients, epileptiform activity in one patient, both in four patients).

A normalized map of cortical $T_2$ values for a single representative subject is shown in Figure 1. Mean cortical $T_2$ values were significantly increased ($P = 0.01$) in the patient group (group mean $\pm$ SD: 83.4 $\pm$ 2.1 msec) compared to the control group (81.4 $\pm$ 2.1 msec). The cortical $T_2$ values in the patient group were neither correlated with the number of seizures in 3 months ($r = 0.16$, $P = 0.55$), nor the number of anticonvulsive drugs in medical history ($r = 0.09$, $P = 0.74$). Cortical $T_2$ values were also increased in the subgroup with 11 patients with a low seizure rate (82.9 $\pm$ 1.3 msec, $P = 0.026$).

Figure 2 presents regions with cortical $T_2$ differences between groups. The spatial distribution of the clusters in Fig. 2 after correction for multiple comparisons demonstrates
that, for the investigated cohort of FCD patients, cortical T2 increases were mainly observed for the frontal and parietal lobes. However, the uncorrected maps suggest that a T2 increase might also be present in some temporal regions. Surface-based analysis of the cortical thickness after correction for multiple comparisons revealed no clusters of a significant increase or decrease in cortical thickness. Mean unilateral cortical T2 values in the patient group did not differ between the hemisphere where the FCD was located (83.5 ± 2.6 msec) and the contralateral hemisphere (83.2 ± 1.9 msec, P = 0.67). Figure 3 demonstrates surface maps of the FCD locations of all patients, the red/yellow color indicating the presence of an FCD in one/two patients at the respective locations.

Discussion
Our study used T2 relaxometry and surface-based analysis techniques to investigate normal-appearing cortical tissue in epilepsy patients with FCD. Widespread cortical T2 increases in frontal, parietal, and some temporal regions were observed in the patient group, suggesting effects of the disease in cortical regions beyond FCD areas.

The underlying microstructural changes for the T2 differences we observed are not known. However, a previous investigation reported that gliosis correlated with a hippocampal T2 increase in temporal lobe epilepsy.31 These results indicate that gliosis might either cause an increase of the tissue parameter T2 or affect the T2 measurement. Although pathological immunoreactivity outside the FCD was not observed in an immunohistochemical study by Rossini et al.,3 gliosis on a microstructural level is a candidate for a remodeling process which might explain the observed T2 increases. Importantly, clusters indicating atrophy were not observed in the investigated cohort, which is in line with a previous study demonstrating hippocampal T2 changes in temporal lobe epilepsy, even in patients showing no signs of atrophy.14 Furthermore, it has been reported that hippocampal gliosis may occur without atrophy.32 Since T2 depends on the free water content in tissue,12,13 cortical reconstruction characterized by tissue damage and replacement of cells in nervous tissue by water on a microstructural level could potentially be another mechanism leading to increased cortical T2 values in epilepsy patients with FCD.

However, factors driving these tissue changes in epilepsy are not yet fully understood. Cortical T2 changes in epilepsy patients with FCD might be caused by seizure activity. It should be noted that, to the best of our knowledge, none of the investigated patients had experienced a status epilepticus at the time of this study. Since seizures might contribute to hippocampal gliosis in temporal lobe epilepsy,9 the pathogenesis of the observed tissue changes might also be related to seizure activity. However, both in our study and in a previous investigation by Liu et al.,5 which evaluated atrophy in patients with epilepsy longitudinally, no significant relationship between structural parameters and seizure recurrence was observed. Furthermore, in the present study T2 changes were also observed in the subgroup with a lower seizure rate. Additionally, multiple antiepileptic drug exposure might be another risk factor for neocortical damage in epilepsy.5 However, a significant correlation of cortical T2 values in the patient group and the number of anticonvulsive drugs in the medical history was not observed in our study. As it is likely that multiple factors contribute to the widespread T2 increases, more extensive relaxometry studies might better characterize and separate the different effects.

It should be noted that, although cerebellar atrophy is a common finding in patients with long-standing epilepsies, particularly under treatment with anticonvulsive drugs,7 the cerebral cortex was deemed a better target for qMRI analysis in epilepsy patients with FCD for the following reason: The cerebellar cortical layer is relatively thin and tightly folded.
Therefore, analysis of cerebellar T2 values would result in strong partial volume effects, and thus increase the variability of average T2 values in cerebellar WM and GM across the groups, rendering group comparisons difficult. For the analysis of the cerebral cortex, T2 values were read in the central 20% of the cortical layer to reduce partial volume effects. This approach would not be feasible for the thin cerebellar cortex, considering the given resolution.

FIGURE 2: Cortical areas with T2 differences between groups, hot colors indicating a T2 increase for patients. The top two rows demonstrate uncorrected P values and the bottom two rows clusters after correction for multiple comparisons. The right/left hemisphere is presented in the first/second column, respectively. The lateral view is shown in the first and third row and the medial view in the second and last row.
Several volumetric studies have demonstrated cortical changes,\textsuperscript{4,5,11} suggesting that epilepsy might systemically affect the brain beyond underlying focal lesions. Observations included multifocal abnormalities in GM volume in patients with malformations of cortical development,\textsuperscript{4} focal neocortical volume loss in 14% and generalized volume loss in 41% of patients with chronic epilepsy,\textsuperscript{5} and extratemporal cortical atrophy in temporal lobe epilepsy.\textsuperscript{11} In our study, cortical atrophy was not observed, indicating that T\textsubscript{2} relaxometry might be more sensitive for the assessment of cortical tissue changes in epilepsy, particularly in smaller cohorts. Additionally, a diffusion tensor imaging study by Rugg-Gunn et al. reported abnormal anisotropy and diffusivity in areas that appeared to be normal on conventional images in patients with epilepsy and cerebral lesions.\textsuperscript{33} In our study, cortical T\textsubscript{2} values in the patient group did not differ between the hemisphere where the FCD is located and the contralateral side, also supporting a global character of tissue changes. It is unclear so far whether tissue abnormalities outside focal lesions exhibit an epileptogenic potential. However, in a previous study regions with increased diffusivity matched areas of epileptiform EEG activity in some patients with normal conventional MRI findings.\textsuperscript{33}

**Limitations**

A limitation of the study is the potential risk of underestimating cortical T\textsubscript{2} increases in patients in the surface-based analysis. When analyzing data obtained from patients with a cerebral lesion, the question arises how to exclude the lesion and how to handle this region in the further steps of the analysis. A potential procedure would be to fill the lesion with average values taken from the surrounding cortex (“lesion filling”). However, since T\textsubscript{2} values are increased in normal-appearing cortex in patients, this approach may yield a focal overestimation of the T\textsubscript{2} increase in the epilepsy group. Here, a more conservative approach was followed, by calculating the GLM analysis for each vertex only for the patients for whom cortical T\textsubscript{2} values outside the FCD were available, ie, excluding patients who showed an FCD in the respective region. Further limitations are the small sample size and the relatively long MRI acquisition time.

**Conclusion**

The observed widespread cortical T\textsubscript{2} increases suggest cortical remodeling on a global level in normal-appearing cortex in epilepsy patients with FCD. However, the etiology of these cortical changes is not fully understood, and it is likely that a combination of multiple factors contributes to cortical abnormalities in the tissue composition in patients with epilepsy and FCD.

**Conflicts of Interest**

The authors report no conflicts of interest relevant to this study. Dr. E. Hattingen has received speaker’s honoraria from...
BRACCO. Dr. F. Rosenow has received honoraria for presentations and consultations from EISAI, UCB Pharma, Desitin Arzneimittel, Hexal, Novartis, Medtronic, GW-Pharma, Shire, Sandoz, and Cerbomed, as well as research grants from UCB, European Union, Deutsche Forschungsgemeinschaft, European Science Foundation and the Hessian Ministries of Science and Arts and of Social Affairs and Integration. Dr. H. Steinmetz has received speaker’s honoraria from Bayer, Sanofi, and Boehringer Ingelheim. The remaining authors have no conflicts of interest.

**Data Accessibility Statement**

Data and code are not available publicly or upon direct request because data sharing does not comply with the institutional ethics approval.

**REFERENCES**

1. Gaitanis JN, Donahue J. Focal cortical dysplasia. Pediatr Neurol 2013; 49:79-87.
2. Blümcke I, Thom M, Aronica E, et al. The clinicopathologic spectrum of focal cortical dysplasias: A consensus classification proposed by an ad hoc task force of the ILAE diagnostic methods commission. Epilepsia 2011;52:158-174.
3. Rossini L, Garbelli R, Gnatkovsky V, et al. Seizure activity per se does not induce tissue damage markers in human neocortical focal epilepsy. Ann Neurol 2017;82:331-341.
4. Woermann FG, Free SL, Koepp MJ, Ashburner J, Duncan JS. Voxel-by-voxel comparison of automatically segmented cerebral gray matter—A rater-independent comparison of structural MRI in patients with epilepsy. Neuroimage 1999;10:373-384.
5. Liu RSN, Lemieux L, Bell GS, et al. Progressive neocortical damage in epilepsy. Ann Neurol 2003;53:312-324.
6. Latour P, Biraben A, Polard E, et al. Drug induced encephalopathy in six epileptic patients: Topiramate? Valproate? Or both? Hum Psychopharmacol 2004;19:193-203.
7. de Marcos FA, Ghizoni E, Kobayashi E, Li LM, Cendes F. Cerebellar volume and long-term use of phenytoin. Seizure 2003;12:312-315.
8. Donaire A, Carreno M, Gómez B, et al. Cortical laminar necrosis related to prolonged focal status epilepticus. J Neurol Neurosurg Psychiatry 2006;77:104-106.
9. Walker MC. Hippocampal sclerosis: Causes and prevention. Semin Neurol 2015;35:193-200.
10. Fauser S, Schulze-Bonhage A, Honegger J, et al. Focal cortical dysplasia in children: Surgical outcome in 67 patients in relation to histological subtypes and dual pathology. Brain 2004;127:2406-2418.
11. Caciagli L, Bernasconi A, Wiebe S, Koepp MJ, Bernasconi N, Bernhardt BC. A meta-analysis on progressive atrophy in intractable temporal lobe epilepsy: Time is brain? Neurology 2017;89:506-516.
12. Cercignani M, Dowell NG, Tofts P, editors. Quantitative MRI of the brain. Principles of physical measurement. Boca Raton, FL: CRC Press Taylor & Francis Group; 2018.
13. Deoni SCL, Rutt BK, Arun T, Pierpaoli C, Jones DK. Gleaning multicompontent T1 and T2 information from steady-state imaging data. Magn Reson Med 2006;50:1372-1387.
14. Bernasconi A, Bernasconi N, Caramanos Z, et al. T2 relaxometry can lateralize mesial temporal lobe epilepsy in patients with normal MRI. Neuroimage 2000;12:739-746.

Ahmad et al.: Cortical Changes Beyond FCD
15. Cantor-Rivera D, Khan AR, Goubri M, Mirsattari SM, Peters TM. Detection of temporal lobe epilepsy using support vector machines in multi-parametric quantitative MR imaging. Comput Med Imaging Graphics 2015;41:14-28.
16. Winston GP, Vos SB, Burdett JL, Cardoso MJ, Ourselin S, Duncan JS. Automated T2 relaxometry of the hippocampus for temporal lobe epilepsy. Epilepsia 2017;58:1645-1652.
17. Vos SB, Winston GP, Goodkin O, et al. Hippocampal profiling: Localized magnetic resonance imaging volumetry and T2 relaxometry for hippocampal sclerosis. Epilepsia 2020;61:297-309.
18. Reeves C, Tachfouti M, Thomas D, et al. Combined ex vivo 9.4T MRI and quantitative histopathological study in normal and pathological neocortical resections in focal epilepsy. Brain Pathol. 2016;26:319-333.
19. Gracien R-M, van Wijnen A, Maiworm M, et al. Improved synthetic T1-weighted images for cerebral tissue segmentation in neurological diseases. Magn Reson Imaging 2019;61:158-166.
20. (Maiworm et al. 2020, submitted).
21. Nöth U, Gracien R-M, Maiworm M, et al. Detection of cortical malformations using enhanced synthetic contrast images derived from quantitative T1 maps. NMR Biomed 2020;33:e4203.
22. Fischl B, Salat DH, van der Kouwe A, et al. Sequence-independent segmentation of magnetic resonance images. Neuroimage 2004;23(Suppl 1):S69-S84.
23. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;23(Suppl 1):19.
24. McPhee KC, Wilman AH. T2 quantification from only proton density and T2-weighted MRI by modelling actual refocusing angles. Neuroimage 2015;118:642-650.
25. Nöth U, Shrestha M, Schure J-R, Deichmann R. Quantitative in vivo T2 mapping using fast spin echo techniques—A linear correction procedure. Neuroimage 2017;157:476-485.
26. Gracien R-M, Maiworm M, Brüche N, et al. How stable is quantitative MRI? – Assessment of intra- and inter-scanner-model reproducibility using identical acquisition sequences and data analysis programs. Neuroimage 2020;207:116364.
27. Greve DN, Fischl B. Accurate and robust brain image alignment using boundary-based registration. Neuroimage 2009;48:63-72.
28. Kim ES, Yoon DY, Lee H-Y, KJY, Han A, Yoon SJ, Kim HC. Comparison of emergency cranial CT interpretation between radiology residents and neuroradiologists: Transverse versus three-dimensional images. Diagn Interv Radiol 2014;20:277-284.
29. Gracien R-M, Reitz SC, Hof S-M, et al. Longitudinal quantitative MRI assessment of cortical damage in multiple sclerosis. A pilot study. J Magn Reson Imaging 2017;46:1485-1490.
30. van Wijnen A, Petrov F, Maiworm M, et al. Cortical quantitative MRI parameters are related to the cognitive status in patients with relapsing-remitting multiple sclerosis. Eur Radiol 2020;30:1045-1053.
31. Peixoto-Santos JE, Kandratavicius L, Velasco TR, et al. Individual hippocampal subfield assessment indicates that matrix macromolecules and gliosis are key elements for the increased T2 relaxation time seen in temporal lobe epilepsy. Epilepsia 2017;58:149-159.
32. Hattingen E, Enkirch SJ, Jurcoane A, et al. Hippocampal “gliosis only” on MR imaging represents a distinct entity in epilepsy patients. Neuro-radiology 2018;60:161-168.
33. Rugg-Gunn FJ, Eriksson SH, Symms MR, Barker DJ, Duncan JS. Diffus-